About Parallel Bio
Parallel Bio is a Healthcare company based in Cambridge (United States) founded in 2020. It operates as a limited information available. Parallel Bio has raised $25.43 million across 3 funding rounds from investors including Refactor Capital, Y Combinator and AIX Ventures. The company has 6 employees. Parallel Bio offers products and services including Immune Organoids Platform and AI Drug Discovery Service. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Drug Discovery. Its legal entity is PARALLEL BIOSYSTEMS INC. Its competitors include Newcells Biotech, InSphero, Pandorum, Vivodyne and Adapsyn and 4 more; 6 of its 9 listed competitors have raised funding.
Company details
Parallel Bio was founded in 2020 and is located in Cambridge, United States. The companys domain, parallel.bio, serves as its primary online identifier. Limited details are available concerning its industry sector, specific operations, or services provided. Further information on core activities remains undisclosed in public sources at this time.
- Headquarters Cambridge, United States
- Employees 6
- SectorsHealthcare
- Email••••••••
- Website parallel.bio
- Social LinkedIn X
- Legal Name Parallel Biosystems Inc.
- Total Equity Funding$25.43M (USD)
in 3 rounds
- Latest Funding Round$21M (USD), Series A
Jun 2025
- InvestorsRefactor Capital
& 8 more
- Employee Count6
Products & Services of Parallel Bio
Parallel Bio offers a comprehensive portfolio of products and services, including Immune Organoids Platform and AI Drug Discovery Service.
Enables in-vitro testing of drugs using human immune replicas.
Uses AI to analyze immune data for faster drug candidate verification.
Funding Insights of Parallel Bio
Parallel Bio has successfully raised a total of $25.43M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $21 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $25.43M
- Total Rounds 3
- Last Round Series A — $21M
- First Round $125,000
(Jun 2021)
- Investors Count 9
All 3 funding rounds of Parallel Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2025 | $21M | Series A | – | AIX Ventures | |
| Jan 2023 | $4.3M | Seed | – | Refactor Capital | – |
| Jun 2021 | $125,000 | Seed | – | Y Combinator | – |
9 investors in total: 7 institutional and 2 angel.
Investors in Parallel Bio
Parallel Bio has secured backing from 9 investors, including venture fund and angel investors. Prominent investors backing the company include Refactor Capital, Y Combinator and AIX Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed and early-stage investments are made across US and India. | – | refactor.com | Burlingame, United States | |
Early-stage startups are accelerated via funding and educational programs. | – | ycombinator.com | Mountain View, United States | |
Venture capital is provided to AI-powered companies by AIX Ventures. | – | aixventures.com | Palo Alto, United States | |
Metaplanet is recognized as an evergreen investment firm focused on deep tech. | – | metaplanet.com | Tallinn, Estonia | |
Humba Ventures is engaged in investing in deep tech startups. | – | humbaventures.com | - | |
Atypical Ventures is focused on early-stage investments for technical founders. | – | atypical.com | - | |
Early-stage venture capital investments are made in technology and biotech. | – | undeterredcapital.com | - | |
MB Marc Benioff | - | – | unknown_f54cb580e22345f0a | - |
JD Jeff Dean | - | – | unknown_0f669179453f416d9 | - |
Investor details for Parallel Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Parallel Bio
7 people are tracked at Parallel Bio (6 in leadership, 1 in team); the tracked headcount is 6.
| Name | Role | Group |
|---|---|---|
Mary Clare McFadden | Director Of Talent Acquisition | Leadership |
Juliana L. | Co-Founder & CSO | Leadership |
Amanda Gregg | VP Of People Operations | Leadership |
Robert M. DiFazio | Co-Founder & CEO | Leadership |
Juliana L. Hilliard | Co-Founder & CSO | Leadership |
Ari Gesher | Head Of Technology | Leadership |
Elliot H. | Principal Automation Engineer | Team |
Complete people profiles for Parallel Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Parallel Bio
3 dated milestones of Parallel Bio across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Parallel Bio is founded.
- Funding First funding round of $125K.
- Funding Latest funding round, Series A, of $21.0M.
Competitors of Parallel Bio
Parallel Bio has 9 listed competitors in our database, 6 of them funded. They include Newcells Biotech, InSphero, Pandorum, Vivodyne and Adapsyn, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| newcellsbiotech.co.uk | 2014 | Newcastle Upon Tyne, United Kingdom | $14.43M | 22 | Induced pluripotent stem cell-derived organoid models are developed for research. | |
| insphero.com | 2009 | Schlieren, Switzerland | $35.02M | – | Cell-based assays and 3D microtissues for drug screening are developed. | |
| pandorum.com | 2011 | Bengaluru, India | $36.82M | 28 | Regenerative medicine and 3D tissues are developed for therapeutic uses. | |
| vivodyne.com | 2021 | Philadelphia, United States | $117.69M | – | Developer of AI-based platform for lab-grown human tissues | |
| adapsyn.com | 2016 | Hamilton, United States | – | – | Provider of computational tools for bacterial metabolomic and genomic data analysis | |
| cellesce.com | 2013 | Cardiff, United Kingdom | – | 9 | Scalable processes for organoid expansion are developed. | |
| vyantbio.com | 1999 | Cherry Hill, United States | $10.5M | 25 | Developer of drug discovery platform | |
| nextvivo.bio | 2021 | Palo Alto, United States | $7.9M | 8 | Immune-competent human-derived models are developed for drug discovery applications. | |
| fluidformbio.com | 2017 | Waltham, United States | – | 19 | 3D bioprinting solutions for engineered tissues are developed. |
Detailed competitors of Parallel Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Parallel Bio
The website of Parallel Bio (parallel.bio) receives about 2.4K visits a month.
- Monthly visits2.4K
▲ 39.2% vs previous month
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Parallel Bio (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Parallel Bio
Complete news archive for Parallel Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Parallel Bio
Parallel Bio was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Parallel Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Parallel Bio is a funded company, having raised a total of $25.43M across 3 funding rounds to date. The company's 1st funding round was a Seed of $125K, raised on Jun 2021.
Parallel Bio has 6 employees.
Parallel Bio was founded in 2020 and is located in Cambridge, United States. The companys domain, parallel.bio, serves as its primary online identifier. Limited details are available concerning its industry sector, specific operations, or services provided. Further information on core activities remains undisclosed in public sources at this time.
Parallel Bio's top competitors include Newcells Biotech, InSphero and Vivodyne.
Parallel Bio offers Immune Organoids Platform and AI Drug Discovery Service.
Parallel Bio has 9 investors. Key investors include Refactor Capital, Y Combinator, AIX Ventures, Marc Benioff, and Metaplanet.
Parallel Bio operates through Parallel Biosystems Inc..